223 related articles for article (PubMed ID: 22000749)
1. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract][Full Text] [Related]
2. How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation?
Vilkin A; Halpern M; Morgenstern S; Brazovski E; Gingold-Belfer R; Boltin D; Purim O; Kundel Y; Welinsky S; Brenner B; Niv Y; Levi Z
Hum Pathol; 2014 Oct; 45(10):2029-36. PubMed ID: 25150747
[TBL] [Abstract][Full Text] [Related]
3. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
4. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
[TBL] [Abstract][Full Text] [Related]
6. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
Alakus H; Bollschweiler E; Hölscher AH; Warnecke-Eberz U; Frazer KA; Harismendy O; Lowy AM; Mönig SP; Eberz PM; Maus M; Drebber U; Siffert W; Metzger R
Ann Surg Oncol; 2014 Dec; 21(13):4375-82. PubMed ID: 24986238
[TBL] [Abstract][Full Text] [Related]
7. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
Kishi K; Doki Y; Yano M; Yasuda T; Fujiwara Y; Takiguchi S; Kim S; Higuchi I; Monden M
Clin Cancer Res; 2003 Oct; 9(12):4368-75. PubMed ID: 14555508
[TBL] [Abstract][Full Text] [Related]
8. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy for esophageal carcinoma.
Zhang X; Watson DI; Jamieson GG; Bessell JR; Devitt PG
Dis Esophagus; 2005; 18(2):104-8. PubMed ID: 16053485
[TBL] [Abstract][Full Text] [Related]
11. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
12. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
13. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.
Hammoud ZT; Kesler KA; Ferguson MK; Battafarrano RJ; Bhogaraju A; Hanna N; Govindan R; Mauer AA; Yu M; Einhorn LH
Dis Esophagus; 2006; 19(2):69-72. PubMed ID: 16643172
[TBL] [Abstract][Full Text] [Related]
16. Low hMLH1 expression prior to definitive chemoradiotherapy predicts poor prognosis in esophageal squamous cell carcinoma.
Nam TK; Lee JH; Cho SH; Chung IJ; Ahn SJ; Song JY; Yoon MS; Chung WK; Nah BS
Cancer Lett; 2008 Feb; 260(1-2):109-17. PubMed ID: 18053639
[TBL] [Abstract][Full Text] [Related]
17. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing.
Chiam K; Mayne GC; Watson DI; Woodman RJ; Bright TF; Michael MZ; Karapetis CS; Irvine T; Phillips WA; Hummel R; Wang T; Pimlott LK; Marri S; Astill DS; Ruszkiewicz AR; Thompson SK; Hussey DJ
Ann Surg Oncol; 2018 Sep; 25(9):2731-2738. PubMed ID: 29987600
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Duong C; Greenawalt DM; Kowalczyk A; Ciavarella ML; Raskutti G; Murray WK; Phillips WA; Thomas RJ
Ann Surg Oncol; 2007 Dec; 14(12):3602-9. PubMed ID: 17896157
[TBL] [Abstract][Full Text] [Related]
19. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
20. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
